Keytruda (pembrolizumab): Insurance Coverage and Denials
A plain-language guide to PD-1 immune checkpoint inhibitor coverage, why insurers deny it, and where to get cancer-specific help.
Keytruda is an immunotherapy known as a PD-1 blocking antibody. By binding the PD-1 receptor on immune T cells, it releases a brake that some tumors use to evade the immune system, allowing the body's own defenses to attack cancer cells. The FDA has approved Keytruda across many cancers, including certain non-small cell lung, melanoma, head and neck, cervical, and other tumor types, often based on biomarkers such as PD-L1 expression or MSI-H or dMMR status.
Insurers commonly require prior authorization for Keytruda and frequently demand documentation of the specific biomarker, tumor type, and line of therapy that match the approved use. Denials and delays often arise from missing biomarker test results, questions about combination regimens, or site-of-care policies steering infusions away from hospital outpatient settings.
If your plan denies coverage, you generally have the right to an internal appeal and then an independent external review, protections grounded in federal rules such as 45 CFR 147.136. For hands-on cancer help, contact the PAN Foundation, Patient Advocate Foundation, Triage Cancer, CancerCare, or Merck's Keytruda copay and patient-assistance programs.
Where to get cancer-specific help
A note on scope. Apellica focuses on appeals for non-oncology insurance denials and does not handle cancer-related appeal cases. Cancer coverage involves complex, fast-moving clinical and financial questions, and patients are best served by organizations built specifically for oncology. If you are facing a cancer drug denial, please reach out to the specialized groups listed on this page, including the PAN Foundation, the Patient Advocate Foundation, Triage Cancer, and CancerCare, along with the manufacturer's own copay or patient-assistance program. They offer free, expert, cancer-focused support, and they can help you understand your options and protect your access to treatment. ---
- PAN Foundation Copay and financial assistance funds for specific diagnoses.
- Patient Advocate Foundation Case managers who help with insurance denials and appeals for serious illness.
- Triage Cancer Free education and resources on cancer-related insurance and appeals.
- CancerCare Professional support services and financial assistance.
Oncology clinics and manufacturers
Apellica partners with infusion centers, oncology practices, and pharmaceutical manufacturers on denial recovery and patient access at scale. If you are exploring a partnership, we would like to talk.
Partner with usFrequently asked questions
- Why do insurers deny Keytruda?
- Prior authorization or required clinical criteria not documented; Line-of-therapy or biomarker (PD-L1) requirements; Site-of-care (infusion location) restrictions; Off-label or compendia-support questions.
- Can I appeal a Keytruda denial?
- Yes. You generally have the right to an internal appeal and then an independent external review under federal rules such as 45 CFR 147.136. For cancer-specific help, the organizations listed on this page specialize in oncology coverage.